SCHEMBL15028238

SCHEMBL15028238

CN(C)CCCC(=O)OC(CCCCCCCCC(=O)O)CCCCCCCCC(=O)OC1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KDM4A O75164 11/20 0.34
▸ KDM4C Q9H3R0 11/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM7A Q6ZMT4 1/20 0.34
▸ PHF8 Q9UPP1 1/20 0.34
▸ KDM2A Q9Y2K7 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GMNN O75496 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15026848 0.95 NAAA (0.55) NAAASMN1; SMN2LMNAHDAC4HDAC1
SCHEMBL16376200 0.95 NAAA (0.55) NAAASMN1; SMN2LMNAHDAC4HDAC1
SCHEMBL15009576 0.95 NAAA (0.55) NAAASMN1; SMN2LMNAHDAC4HDAC1
SCHEMBL15009586 0.94 NAAA (0.54) NAAASMN1; SMN2LMNAHDAC4HDAC1
SCHEMBL15027493 0.94 NAAA (0.54) NAAASMN1; SMN2LMNAHDAC4HDAC1
SCHEMBL31323892 0.94 NAAA (0.52) NAAASMN1; SMN2LMNATSHRHDAC4
SCHEMBL29190226 0.91 NAAA (0.64) NAAASMN1; SMN2LMNATSHRHIF1A
SCHEMBL517835 0.85 KDM4A (0.44) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL20490773 0.85 KDM4A (0.44) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL15027342 0.85 KDM4A (0.44) KDM4AKDM4CKDM5AKDM7APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788316-B1 BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS INC (US) 2019-04-24 — — EP disclosed
US-9463247-B2 Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-10-11 — — US disclosed
US-9463247-B2 Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-10-11 — — US disclosed
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents BANK OF AMERICA, N.A. 2015-01-01 — — US disclosed
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents BANK OF AMERICA, N.A. 2015-01-01 — — US disclosed
WO-2013086322-A1 BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents LIPA, CETP, APOB NAAA 1178/4885SMN1; SMN2 2502/4885KDM4A 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback